A Phase 3 interventional study of Losartan 50 mg and Losartan 150 mg in Heart Failure, sponsored by Organon and Co. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-16.
Sponsored by Organon and Co · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a multicenter study to evaluate potential decrease in hospitalization events and time between events and increasing longevity in patients with symptomatic congestive heart failure and intolerant of first-line medication for heart failure. This study will evaluate if higher doses of the investigational drug given daily will be superior to the lower dose of the same investigational drug given daily.
6,334 studies on the registry are indexed under Heart Failure; 1,394 are open to participants now.
This study's enrollment of 3,834 is above the median of 76 across 4,049 interventional studies indexed under Heart Failure.
Browse Heart Failure studies →Organon and Co is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 23 completed or terminated interventional studies of FDA-regulated products, 18 (78%) have results posted.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
50-mg losartan tablet administered daily with 1 tablet of 100-mg losartan placebo beginning Week 1 and continuing to end of study (up to 4 years)
Drug: Losartan 50 mg
Titrated losartan administration up to daily 150-mg losartan: Week 1, daily 50-mg losartan tablet coadministered with 100-mg losartan placebo; Week 2, daily 50-mg losartan placebo coadministered with 100-mg losartan; Week 3 to end of study (up to 4 years), daily 50-mg losartan tablet coadministered with 100-mg losartan
Drug: Losartan 150 mg
50-mg losartan oral tablet
Also known as: Losartan potassium
100-mg losartan oral tablet + 50-mg losartan oral tablet
Also known as: Losartan potassium
Number of Participants That Experienced One Component of the Composite Clinical Endpoint of All Cause Death or Hospitalization for Heart Failure
Time frame: Entire follow-up (median = 4.7 years)
Number of Participants That Experienced One Components of the Composite Clinical Endpoint of All Cause Death or Cardiovascular Hospitalization
Cardiovascular hospitalization is defined as any hospitalization that may be attributed to a cardiovascular cause, including heart failure.
Time frame: Entire follow-up (median = 4.7 years)
Number of Participants That Died (Any Cause)
Time frame: Entire follow-up (median = 4.7 years)
Number of Participants That Were Hospitalized for Heart Failure
Time frame: Entire follow-up (median = 4.7 years)
Number of Participants That Experienced Cardiovascular Hospitalization
Time frame: Entire follow-up (median = 4.7 years)
First patient in: Nov-2001. Last patient out: May-2009. 255 sites in 30 countries participated (Peru , Chile, Columbia, Mexico, Brazil, Belgium, Croatia, France, Germany, Greece, Holland, Italy, Norway, Poland, Russia, Slovenia, Spain, Turkey, UK, Egypt, Lebanon, Morocco, S. Africa, China, Hong Kong, Korea, Malaysia, Philippines, Singapore, Taiwan)
| Milestone | Losartan 50 mg | Losartan 150 mg |
|---|---|---|
| Started | 1913 | 1921 |
| Completed | 1851 | 1873 |
| Not completed | 62 | 48 |
| Withdrew: Lost to follow-up | 30 | 26 |
| Withdrew: Withdrawal by subject | 21 | 15 |
| Withdrew: Investigator site closed | 11 | 7 |
| Participants | Losartan 50 mg | Losartan 150 mg |
|---|---|---|
| Number of Participants That Experienced One Component of the Composite Clinical Endpoint of All Cause Death or Hospitalization for Heart Failure | 889 | 828 |
Cardiovascular hospitalization is defined as any hospitalization that may be attributed to a cardiovascular cause, including heart failure.
| Participants | Losartan 50 mg | Losartan 150 mg |
|---|---|---|
| Number of Participants That Experienced One Components of the Composite Clinical Endpoint of All Cause Death or Cardiovascular Hospitalization | 1085 | 1037 |
| Participants | Losartan 50 mg | Losartan 150 mg |
|---|---|---|
| Number of Participants That Died (Any Cause) | 665 | 635 |
| Participants | Losartan 50 mg | Losartan 150 mg |
|---|---|---|
| Number of Participants That Were Hospitalized for Heart Failure | 503 | 450 |
| Participants | Losartan 50 mg | Losartan 150 mg |
|---|---|---|
| Number of Participants That Experienced Cardiovascular Hospitalization | 826 | 762 |
Collected over All adverse experiences that occurred during or up to 14 days after permanent or temporary discontinuation of the study treatment were included in the safety analyses. Per guidelines, endpoints were not reported as serious adverse experiences.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Losartan 50 mg | — | 691/1,913 (36.1%) | 1,358/1,913 (71%) |
| Losartan 150 mg | — | 710/1,921 (37%) | 1,394/1,921 (72.6%) |
| Event | Losartan 50 mg | Losartan 150 mg |
|---|---|---|
| PneumoniaInfections and infestations | 88/1913 | 72/1921 |
| Renal failureRenal and urinary disorders | 33/1913 | 43/1921 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 26/1913 | 28/1921 |
| AnaemiaBlood and lymphatic system disorders | 19/1913 | 24/1921 |
| Renal failure acuteRenal and urinary disorders | 21/1913 | 21/1921 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 15/1913 | 21/1921 |
| SepsisInfections and infestations | 18/1913 | 20/1921 |
| GastroenteritisInfections and infestations | 17/1913 | 19/1921 |
| Inguinal herniaGastrointestinal disorders | 18/1913 | 11/1921 |
| BronchitisInfections and infestations | 18/1913 | 12/1921 |
| Event | Losartan 50 mg | Losartan 150 mg |
|---|---|---|
| Blood creatinine increasedGeneral disorders | 163/1913 | 285/1921 |
| DizzinessNervous system disorders | 254/1913 | 245/1921 |
| Cardiac failureCardiac disorders | 231/1913 | 200/1921 |
| BronchitisInfections and infestations | 231/1913 | 222/1921 |
| Blood urea increasedGeneral disorders | 159/1913 | 222/1921 |
| NasopharyngitisInfections and infestations | 170/1913 | 195/1921 |
| CoughRespiratory, thoracic and mediastinal disorders | 179/1913 | 170/1921 |
| HypotensionVascular disorders | 127/1913 | 178/1921 |
| Blood uric acid increasedGeneral disorders | 150/1913 | 167/1921 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 166/1913 | 152/1921 |
| Age, Continuous(years) | Losartan 50 mg | Losartan 150 mg | Total |
|---|---|---|---|
| Mean | 64.1 (19 to 95) | 64.4 (18 to 98) | 64.2 (18 to 98) |
| Age, Customized(participants) | Losartan 50 mg | Losartan 150 mg | Total |
|---|---|---|---|
| < 65 years of Age | 889 | 879 | 1768 |
| >=65 years of Age | 1024 | 1042 | 2066 |
| Sex: Female, Male(Participants) | Losartan 50 mg | Losartan 150 mg | Total |
|---|---|---|---|
| Female | 560 | 583 | 1143 |
| Male | 1353 | 1338 | 2691 |
| Angiotensin II antagonists(Participants) | Losartan 50 mg | Losartan 150 mg | Total |
|---|---|---|---|
| No | 456 | 438 | 894 |
| Yes | 1457 | 1483 | 2940 |
| New York Heart Association (NYHA) functional status(Participants) | Losartan 50 mg | Losartan 150 mg | Total |
|---|---|---|---|
| I No symptoms | 2 | 1 | 3 |
| II Mild symptoms | 1330 | 1327 | 2657 |
| III Marked limitation | 569 | 583 | 1152 |
| IV Severe limitations | 12 | 10 | 22 |
| Region(participants) | Losartan 50 mg | Losartan 150 mg | Total |
|---|---|---|---|
| Asia and Pacific Region | 391 | 390 | 781 |
| East Europe | 212 | 207 | 419 |
| Middle East and Africa | 97 | 97 | 194 |
| Latin America | 309 | 315 | 624 |
| West Europe | 904 | 912 | 1816 |
| β - Blocker therapy(Participants) | Losartan 50 mg | Losartan 150 mg | Total |
|---|---|---|---|
| No | 543 | 533 | 1076 |
| Yes | 1370 | 1388 | 2758 |
No study locations are listed for this record.
Plan to share: No
Ran from Dec 2001 to primary completion in Mar 2009, 87 months.
Results were first posted in Aug 2010, 1 year 4 months after primary completion.
Of 63 industry-sponsored phase 3 interventional studies under Heart Failure, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 44. This study's 87 months is above that.
Counting every sponsor, half of 150 studies reached it within 39 months; a quarter within 26 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Losartan